Advertisement
REGN vs VRTX
Which Stock Would AI Choose? Regeneron Pharmaceuticals (REGN) vs. Vertex Pharmaceuticals (VRTX) Stock Comparison
Key Takeaways
- REGN (Regeneron Pharmaceuticals) has staged a notable recovery in recent months, rebounding from a mid-2025 low on the back of strong Dupixent growth and new Eylea HD approvals.
- VRTX (Vertex Pharmaceuticals) continues to post double-digit revenue growth, yet softer-than-expected sales from its newer pain and gene-editing therapies have weighed on sentiment.
- Both companies carry analyst consensus ratings in the "Buy" range, but recent momentum and catalyst flow differ meaningfully between the two.
- Tickeron AI Verdict: Based on trend consistency, stability, and recent catalysts, Tickeron's AI currently favors REGN over VRTX as the stronger relative candidate.
- For deeper coverage of each name, explore REGN Major News and REGN Today's Price Move, as well as VRTX Major News and VRTX Today's Price Move.
- To see how automated strategies are positioning across the market, explore the curated Trending AI Robots.
Introduction
Regeneron Pharmaceuticals and Vertex Pharmaceuticals are two of the largest and most closely followed names in the biotechnology sector, yet they operate from very different strategic foundations. Regeneron has built a diversified commercial portfolio spanning ophthalmology, immunology, and oncology, while Vertex has established a near-monopoly in cystic fibrosis (CF) treatment while pushing into pain, kidney disease, and genetic medicine. This stock comparison is relevant for investors seeking to understand how two leading large-cap biotechs differ in growth drivers, risk profiles, and relative performance. Because both stocks are heavily influenced by clinical catalysts and product-launch execution, the comparison is especially useful for traders monitoring sentiment shifts and momentum rather than long-term fundamentals alone.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN) discovers, develops, and commercializes medicines across eye disease, inflammation, cancer, and cardiovascular conditions. Its most important assets include the ophthalmology franchise Eylea and Eylea HD (co-developed with Bayer), the blockbuster immunology drug Dupixent (partnered with Sanofi), the cancer therapy Libtayo, and the cholesterol drug Praluent.
In recent market activity, Regeneron has been rebuilding investor confidence after a difficult stretch earlier in the year. The company faced pressure from Eylea competition—notably Roche's Vabysmo—as well as regulatory and manufacturing setbacks at a third-party facility that delayed certain Eylea applications. However, recent weeks have brought a marked shift. Third-quarter results showed adjusted EPS (earnings per share) of $11.83, comfortably above consensus, while collaboration revenue tied to Dupixent grew strongly as global sales continued to climb. Critically, Eylea HD received two new approvals for retinal vein occlusion and every-four-week dosing, a development analysts described as placing the franchise on firmer footing. This improving catalyst flow has supported a recovery in the share price from its mid-year lows and prompted several firms to raise price targets.
VRTX Overview and Recent Performance
Vertex Pharmaceuticals (VRTX) specializes in treatments for cystic fibrosis and is expanding into pain management, kidney disease, type 1 diabetes, and gene-editing therapies. Its CF portfolio, led by Trikafta/Kaftrio and the newer Alyftrek, remains the core of its business and treats the large majority of eligible CF patients in the United States and Europe.
Vertex's recent performance reflects a solid but uneven picture. Third-quarter revenue rose 11% year over year to $3.08 billion, driven by the CF franchise, and adjusted EPS of $4.80 beat expectations. However, investor enthusiasm was tempered by softer-than-expected sales from two newer products: Journavx, a non-opioid pain medicine, and Casgevy, a gene-editing therapy for sickle cell disease and beta-thalassemia. The stock pulled back following results even as the core CF business delivered. Looking ahead, attention is centered on the company's renal pipeline—particularly povetacicept in IgA nephropathy—and on whether new launches can broaden revenue beyond CF. This blend of a durable core franchise with early-stage, high-expectation products has kept sentiment mixed in recent weeks.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that monitor thousands of tickers, but only a select subset earns a place in the curated Trending AI Robots section. These bots are chosen for their suitability to current market conditions, and each is distinct in trading style, strategy, timeframe, performance history, and the set of tickers it trades. Many bots report measurable performance statistics, allowing users to evaluate win rates, trade frequency, and historical results before following a strategy. Because market regimes change, the bots featured as "trending" are continually refreshed to reflect what is currently performing well. If you are interested in seeing how automated, data-driven strategies are positioning across names like those in this comparison, consider reviewing the Trending AI Robots page.
Head-to-Head Comparison
The two companies differ sharply in diversification and dependency. Regeneron's revenue base is broader, spread across multiple franchises and collaboration partners, which reduces reliance on any single product—though Eylea's competitive erosion remains a key risk. Vertex, by contrast, is far more concentrated: its CF franchise still generates the overwhelming majority of revenue, making the success of newer launches central to its long-term growth narrative.
On momentum, Regeneron has recently benefited from a clear positive catalyst path, including Eylea HD approvals and continued Dupixent strength, supporting a share-price rebound and upward analyst revisions. Vertex's momentum has been more muted, as strong CF results have been offset by disappointment in newer product ramps and higher operating investment. In terms of market positioning, Vertex trades with a larger market capitalization and enjoys a dominant moat in CF, while Regeneron offers a more diversified pipeline and near-term regulatory catalysts. The trade-off for investors is between Vertex's high-margin, durable-but-concentrated franchise and Regeneron's broader portfolio with a recovering momentum profile.
Tickeron AI Verdict
Weighing observable factors such as trend consistency, relative stability, and the direction of recent catalysts, Tickeron's AI currently leans toward REGN as the more favorably positioned of the two. Regeneron's combination of a recovering price trend, newly granted regulatory approvals, sustained Dupixent growth, and a wave of analyst target increases presents a comparatively stronger near-term setup. Vertex remains a high-quality business with a dominant CF franchise and promising pipeline, but softer launch momentum and higher expectations around new products have introduced more uncertainty into its trend. This assessment reflects a probabilistic reading of current data rather than a definitive forecast, and conditions may shift as new clinical and commercial developments emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REGN is a Buy and VRTX is a Buy.
REGN in upward trend: 10-day moving average crossed above 50-day moving average on October 26, 2026
The 10-day moving average for REGN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 62 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for REGN just turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 33 of 50 cases over the following month. The odds of a continued upward trend are 66%.
REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 203 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 186 of 264 cases where REGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
Bearish Trend Analysis
The 10-day RSI Indicator for REGN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 21 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 48%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 64 cases where REGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
REGN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 7 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.936) is normal, around the industry mean (3.498). P/E Ratio (21.599) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (130.981) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (440.869).
VRTX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for VRTX turned positive on October 20, 2026. Looking at past instances where VRTX's MACD turned positive, the stock continued to rise in 42 of 59 cases over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VRTX as a result. In 60 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
VRTX moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VRTX crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 68%.
Following a +1.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRTX advanced for three days, in 235 of 368 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for VRTX moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 22 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 51%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 63 cases where VRTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 54%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 44%.
VRTX broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VRTX entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 21 (best 1 - 100 worst), indicating outstanding price growth. VRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.848) is normal, around the industry mean (3.498). P/E Ratio (31.605) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.939) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (10.449) is also within normal values, averaging (440.869).
REGN | VRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 44 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 64 | 13 | |
SMR RATING 1..100 | 59 | 41 | |
PRICE GROWTH RATING 1..100 | 7 | 21 | |
P/E GROWTH RATING 1..100 | 13 | 37 | |
SEASONALITY SCORE 1..100 | 50 | 47 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (88) in the Biotechnology industry is in the same range as VRTX (91). This means that REGN’s stock grew similarly to VRTX’s over the last 12 months.
VRTX's Profit vs Risk Rating (13) in the Biotechnology industry is somewhat better than the same rating for REGN (64). This means that VRTX’s stock grew somewhat faster than REGN’s over the last 12 months.
VRTX's SMR Rating (41) in the Biotechnology industry is in the same range as REGN (59). This means that VRTX’s stock grew similarly to REGN’s over the last 12 months.
REGN's Price Growth Rating (7) in the Biotechnology industry is in the same range as VRTX (21). This means that REGN’s stock grew similarly to VRTX’s over the last 12 months.
REGN's P/E Growth Rating (13) in the Biotechnology industry is in the same range as VRTX (37). This means that REGN’s stock grew similarly to VRTX’s over the last 12 months.
| REGN | VRTX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 48% | 1 day ago 51% |
| Stochastic ODDS (%) | 1 day ago 63% | 1 day ago 54% |
| Momentum ODDS (%) | 1 day ago 68% | 1 day ago 70% |
| MACD ODDS (%) | 1 day ago 66% | 1 day ago 71% |
| TrendWeek ODDS (%) | 1 day ago 57% | 1 day ago 42% |
| TrendMonth ODDS (%) | 1 day ago 65% | 1 day ago 68% |
| Advances ODDS (%) | 1 day ago 64% | 1 day ago 64% |
| Declines ODDS (%) | 5 days ago 57% | 7 days ago 44% |
| BollingerBands ODDS (%) | 1 day ago 53% | 1 day ago 48% |
| Aroon ODDS (%) | 1 day ago 70% | 1 day ago 42% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
REGN’s FA Score shows that 2 FA rating(s) are green while VRTX’s FA Score has 2 green FA rating(s).
- REGN’s FA Score: 2 green, 3 red.
- VRTX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
REGN’s TA Score shows that 6 TA indicator(s) are bullish while VRTX’s TA Score has 5 bullish TA indicator(s).
- REGN’s TA Score: 6 bullish, 4 bearish.
- VRTX’s TA Score: 5 bullish, 5 bearish.
Price Growth
REGN (@Biotechnology) experienced а -4.30% price change this week, while VRTX (@Biotechnology) price change was -0.41% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.23%. For the same industry, the average monthly price growth was -8.97%, and the average quarterly price growth was +85.13%.
Reported Earning Dates
REGN is expected to report earnings on Jan 29, 2027.
VRTX is expected to report earnings on Feb 09, 2027.
Industries' Descriptions
@Biotechnology (+2.23% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
REGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, REGN has been loosely correlated with VRTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then VRTX could also see price increases.
| Ticker / NAME | Correlation To REGN | 1D Price Change % | ||
|---|---|---|---|---|
| REGN | 100% | +1.73% | ||
| VRTX - REGN | 42% Loosely correlated | +0.69% | ||
| EXEL - REGN | 41% Loosely correlated | +3.12% | ||
| RPRX - REGN | 41% Loosely correlated | +2.18% | ||
| INCY - REGN | 39% Loosely correlated | +1.87% | ||
| BMRN - REGN | 35% Loosely correlated | +2.05% | ||
More | ||||